Tìm theo
Eplerenone
Các tên gọi khác (2) :
  • Epoxymexrenone
  • Inspra
mineralocorticoid receptor antagonists
Thuốc Gốc
Small Molecule
CAS: 107724-20-9
ATC: C03DA04
ĐG : Apotex Inc. , http://www.apotex.com
CTHH: C24H30O6
PTK: 414.4914
Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C24H30O6
Phân tử khối
414.4914
Monoisotopic mass
414.204238692
InChI
InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1
InChI Key
InChIKey=JUKPWJGBANNWMW-VWBFHTRKSA-N
IUPAC Name
methyl (1'R,2R,2'S,9'R,10'R,11'S,15'S,17'R)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0^{1,17}.0^{2,7}.0^{11,15}]octadecan]-6'-ene-9'-carboxylate
Traditional IUPAC Name
eplerenone
SMILES
[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC
Độ hòa tan
Slightly soluble
logP
1.3
logS
-4.7
pKa (strongest acidic)
15.11
pKa (Strongest Basic)
-4.2
PSA
82.2 Å2
Refractivity
106.68 m3·mol-1
Polarizability
43.79 Å3
Rotatable Bond Count
2
H Bond Acceptor Count
4
H Bond Donor Count
0
Physiological Charge
0
Number of Rings
6
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.
Cơ Chế Tác Dụng : Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors. Eplerenone binds to the mineralocorticoid receptor and thereby blocks the binding of aldosterone (component of the renin-angiotensin-aldosterone-system, or RAAS). Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, blood vessels, and brain) tissues and increases blood pressure through induction of sodium reabsorption and possibly other mechanisms.
Dược Động Học :
▧ Absorption :
The absolute bioavailability of eplerenone is unknown.
▧ Volume of Distribution :
* 43 to 90 L
▧ Protein binding :
50%
▧ Metabolism :
Eplerenone is metabolized primarily by CYP3A4, however, no active metabolites have been identified in human plasma.
▧ Half Life :
4-6 hours
▧ Clearance :
* Apparent plasma cl=10 L/hr
Độc Tính : The most likely symptoms of human overdosage would be anticipated to be hypotension or hyperkalemia. However, no cases of human overdosage with eplerenone have been reported.
Chỉ Định : For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.
Tương Tác Thuốc :
  • Amiloride Increased risk of hyperkalemia. Monitor serum potassium levels during concomitant threapy.
  • Bicalutamide CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of eplerenone. A lower starting dose of eplerenone (25 mg once daily) is recommended in patients with hypertension who are also taking drugs that are moderate inhibitors of CYP3A4.
  • Clarithromycin The macrolide, clarithromycin, may increase the effect and toxicity of eplerenone.
  • Conivaptan CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone. The combination of eplerenone with any strong CYP3A4 inhibitor is contraindicated.
  • Erythromycin This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
  • Fluconazole This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
  • Itraconazole Itraconazole may increase the effect and toxicity of eplerenone.
  • Ketoconazole Ketoconazole, a CYP3A4 inhibitor, may increase the effect and toxicity of eplerenone.
  • Lithium Eplerenone increases serum levels of lithium
  • Nefazodone Nefazodone increases the effect and toxicity of eplerenone
  • Nelfinavir The protease inhibitor, nelfinavir, may increase the effect and toxicity of eplerenone.
  • Polystyrene sulfonate Risk of alkalosis in renal impairment
  • Potassium This association presents an increased risk of hyperkalemia
  • Ritonavir This protease inhibitor, ritonavir, may increase the effect and toxicity of eplerenone.
  • Saquinavir This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
  • Spironolactone This association presents an increased risk of hyperkalemia
  • Telithromycin Telithromycin may reduce clearance of Eplerenone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eplerenone if Telithromycin is initiated, discontinued or dose changed.
  • Trandolapril Increased risk of hyperkalemia. Monitor serum potassium levels.
  • Treprostinil Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Triamterene This association presents an increased risk of hyperkalemia
  • Troleandomycin The macrolide, troleandomycin, may increase the effect and toxicity of eplerenone.
  • Verapamil This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
  • Voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eplerenone by decreasing its metabolism. Concomitant therapy is contraindicated.
Liều Lượng & Cách Dùng : Tablet, film coated - Oral
Dữ Kiện Thương Mại
Giá thị trường
  • Biệt dược thương mại : Eplerenone 25 mg tablet
    Giá bán buôn : USD >4.18
    Đơn vị tính : tablet
  • Biệt dược thương mại : Eplerenone 50 mg tablet
    Giá bán buôn : USD >4.18
    Đơn vị tính : tablet
  • Biệt dược thương mại : Inspra 25 mg tablet
    Giá bán buôn : USD >4.87
    Đơn vị tính : tablet
  • Biệt dược thương mại : Inspra 50 mg tablet
    Giá bán buôn : USD >4.87
    Đơn vị tính : tablet
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : INSPRA
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00700
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C12512
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D01115
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0185-5368-30
PharmGKB
http://www.pharmgkb.org/drug/PA164749044
Wikipedia
http://en.wikipedia.org/wiki/Eplerenone
RxList
http://www.rxlist.com/cgi/generic/inspra.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ins1681.shtml
Drugs.com
http://www.drugs.com/cdi/eplerenone.html
... loading
... loading